When was Gero founded?

Gero was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Gero located?

Gero is headquartered in Singapore, Singapore. It is registered at Rīga, Silciema iela 22.

How many employees does Gero have?

As of Aug 31, 2026, the latest employee count at Gero is 139.

Is Gero a funded company?

Gero is a funded company, having raised a total of $25.2M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 2019.

When was the latest funding round of Gero?

Gero's latest funding was a $***** Series A round on Jun 17, 2026, with participation from 1 investor.

What is the annual revenue of Gero?

Annual revenue of Gero is less than $1M as on Dec 31, 2024

Where does Gero rank among its competitors?

Gero ranks 12th amongst 187 active competitors, of which 45 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Gero, which secured $17M in Jun, 2026.

Who are the top competitors of Gero?

Gero's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Galderma. Among them, Gero secured the most recent funding round in June, 2026.

Gero - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of physics based artificial intelligence models for drug discovery. These computational tools analyze longitudinal health records to identify causal pathways and biological targets for therapeutic intervention. The technology distinguishes between reversible disease processes and irreversible physiological damage to inform the design of molecules. This approach focuses on mapping human aging trajectories to facilitate the creation of treatments for age related conditions.

Website: www.gero.ai/
Social
Email ID: *****@gero.ai
Registered Address: Rīga, Silciema iela 22

Key Metrics

Founded Year

2018

Location

Singapore, Singapore

Stage

Series A

Total Funding

$25.2M in 4 rounds

Latest Funding Round

Series A, Jun 17, 2026, $*****

Investors

Bulba Ventures & 14 more

Ranked

12^th among 187 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

139 as on Aug 31, 2026

Investment & Acquisitions

Pickaboo

Similar Companies

OpenEvidence & 2589 more

View Gero's full profile

Gero is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GERO CIN: 40002039456 , Latvia, Active	Nov 16, 1995	€0 - €1M (As on Dec 31, 2022)	2 (As on Dec 31, 2022)	-
GERO PTE. LTD CIN: 201835872R , Singapore, Active		$0 - $1M (As on Dec 31, 2024)	-

Gero has raised a total funding of $25.2M over 4 rounds. Its first funding round was on May 2019. Its latest funding round was a Series A round on Jun 17, 2026 for $*****. 1 investor participated in its latest round. Gero has 5 institutional investors and 10 angel investors.

Here is the list of recent funding rounds of Gero:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2026	7256332	Series A	6350574	6059768	3034032	1311905
Oct 18, 2023	3859889	Series A	7121609	5138424	2543629	VitaDAO
Aug 04, 2020	8799228	Series A	1888955	8571896	Bulba Ventures	9459010

Access funding benchmarks and valuations. Sign up today!

View details of Gero's funding rounds and investors

The founders of Gero is Maxim Kholin.

Here are the details of Gero's key team members:

Maxim Kholin: Co-Founder of Gero and founder of 2 other companies, GeroSense and Gero Discovery.
Contact Info: 1 email address and 1 phone number

Gero's Board of Directors

Gero's board has 4 active members. Maxim Kholin and Peter Fedichev are part of team and Yoo Loo Ping and Vladimir Viktorovich Nesteruk are independent board members.

Here is the list of Gero's board of directors:

Name	Type	Representing	Status	Duration
Maxim Kholin	Team	-	Current	7y 9m
Peter Fedichev	Team	-	Current	6y 11m
Yoo Loo Ping	Independent board member	-	Current	3y 10m
tnxhmxb	Independent board member	-	Current	4y 1m
jlpqkbh	Independent board member	-	Past	1y 1m
mvgh{zp	Independent board member	-	Past	3y 8m
{ebjmho	Independent board member	-	Past	9y 5m

View details of Gero's Founder profiles and Board Members

Gero's employee count trend

Gero has 139 employees as of Aug 26. Here is Gero's employee count trend over the years:

Uncover Gero's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gero include Revance Therapeutics, Lineage Cell Therapeutics and Galderma. Here is the list of Top 10 competitors of Gero, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
3rd	Galderma 1981, Zug (Switzerland), Public	Manufacturer of products to treat a range of dermatological conditions	-	ADIA, Aisling Capital & 1 others	63/100
4th	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	62/100
5th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
6th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	60/100
7th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
8th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Pontifax, Invesco & 4 others	59/100
9th	Clinuvel 2001, Melbourne (Australia), Public	Biopharma company focused on developing drugs for skin disorders	$51.1M	-	58/100
10th	Sinclair 1971, London (United Kingdom), Acquired	Manufacturer of injectable and energy-based device treatments for aesthetic purposes	-	Hayfin, Global Emerging Markets	56/100
12th	Gero 2018, Singapore (Singapore), Series A	Developer of physics based artificial intelligence models for drug discovery	$25.2M	Bulba Ventures, Melnichek Investments & 13 others	56/100